Citigroup
ABEO icon

Citigroup’s Abeona Therapeutics ABEO Stock Holding History

Citigroup’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.34M Buy
522,445
+1,358
+0.3% +$6.79K ﹤0.01% 2572
2025
Q4 		$2.75M Sell
521,087
-2,869
-0.5% -$14.4K ﹤0.01% 2450
2025
Q3 		$2.77M Sell
523,956
-24,101
-4% -$153K ﹤0.01% 2405
2025
Q2 		$3.11M Buy
548,057
+20,499
+4% +$117K ﹤0.01% 2299
2025
Q1 		$2.51M Sell
527,558
-86,163
-14% -$469K ﹤0.01% 2503
2024
Q4 		$3.42M Sell
613,721
-2,947
-0.5% -$18.1K ﹤0.01% 2336
2024
Q3 		$3.9M Buy
616,668
+126,332
+26% +$660K ﹤0.01% 2065
2024
Q2 		$2.08M Buy
490,336
+6,282
+1% +$32K ﹤0.01% 2324
2024
Q1 		$3.51M Buy
484,054
+33,707
+7% +$214K ﹤0.01% 1978
2023
Q4 		$2.26M Buy
450,347
+347
+0.1% +$1.53K ﹤0.01% 2139
2023
Q3 		$1.89M Buy
450,000
+250,000
+125% +$946K ﹤0.01% 2021
2023
Q2 		$806K Buy
+200,000
New +$700K ﹤0.01% 3005
2022
Q2 		– Sell
-3,477
Closed -$27K – 6183
2022
Q1 		$27K Buy
+3,477
New +$23.9K ﹤0.01% 4993
2021
Q2 		– Sell
-168
Closed -$8K – 6089
2021
Q1 		$8K Sell
168
-304
-64% -$16.7K ﹤0.01% 5741
2020
Q4 		$18K Buy
472
+356
+307% +$12.1K ﹤0.01% 6711
2020
Q3 		$3K Sell
116
-309
-73% -$19.5K ﹤0.01% 7187
2020
Q2 		$31K Sell
425
-773
-65% -$53.4K ﹤0.01% 6286
2020
Q1 		$63K Buy
1,198
+309
+35% +$20.6K ﹤0.01% 5750
2019
Q4 		$73K Sell
889
-248
-22% -$17.5K ﹤0.01% 6018
2019
Q3 		$64K Sell
1,137
-982
-46% -$73.5K ﹤0.01% 5968
2019
Q2 		$253K Buy
2,119
+1,512
+249% +$253K ﹤0.01% 5055
2019
Q1 		$111K Sell
607
-7,082
-92% -$1.27M ﹤0.01% 5641
2018
Q4 		$1.37M Buy
7,689
+2,136
+38% +$466K ﹤0.01% 3062
2018
Q3 		$1.78M Buy
5,553
+1,805
+48% +$640K ﹤0.01% 2865
2018
Q2 		$1.5M Buy
3,748
+445
+13% +$194K ﹤0.01% 2951
2018
Q1 		$1.19M Sell
3,303
-1,383
-30% -$514K ﹤0.01% 3091
2017
Q4 		$1.86M Buy
4,686
+768
+20% +$318K ﹤0.01% 2748
2017
Q3 		$1.67M Buy
3,918
+3,900
+21,667% +$1.05M ﹤0.01% 2855
2017
Q2 		$3K Buy
18
+10
+125% +$1.36K ﹤0.01% 6861
2017
Q1 		$1K Hold
8
– – ﹤0.01% 7060
2016
Q4 		$1K Hold
8
– – ﹤0.01% 7100
2016
Q3 		$1K Hold
8
– – ﹤0.01% 6967
2016
Q2 		$0 Sell
8
-367
-98% -$25.1K ﹤0.01% 7040
2016
Q1 		$24K Buy
375
+236
+170% +$15.6K ﹤0.01% 6468
2015
Q4 		$12K Buy
+139
New +$13.9K ﹤0.01% 6727
2015
Q3 		– Sell
-5
Closed -$664 – 7337
2015
Q2 		$1K Buy
+5
New +$751 ﹤0.01% 7260

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's ABEO Position: Q1 2026 in Review

Citigroup increased its Abeona Therapeutics (ABEO) stake by 0.26% in Q1 2026, buying an estimated $6.79K and bringing the position to 522,445 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2572.

Citigroup first reported a position in ABEO in Q2 2015 and has held it in 36 quarters since. The position peaked at $3.9M in Q3 2024. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Citigroup held 522,445 shares of Abeona Therapeutics worth $2.34M as of Q1 2026.
  • Citigroup bought 1,358 Abeona Therapeutics shares in Q1 2026, an estimated $6.79K.
  • Abeona Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2572 holding.
  • Citigroup first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 36 quarters since.
  • Citigroup's Abeona Therapeutics position peaked at $3.9M in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.